Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Recruiting now · Phase 2/Phase 3
Conditions studied: Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
In brief
Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.
Key facts
- Study ID
- NCT05416307
- Run by
- Electra Therapeutics Inc.
- People needed
- 156
- Starts
- 2022-05-19
- Expected to finish
- 2029-06-01
- Last updated by the study team
- 2026-05-26
Who can join
Age: 6 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University College London Hospitals NHS Foundation Trust — London, England - UK, United Kingdom (enrolling)
- Azienda Ospedale Università di Padova — Padova, Italy (enrolling)
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Materno-Infantile Burlo Garofolo — Trieste, Italy (enrolling)
- Amsterdam Universitair Medische Centra - Locatie Academisch Medisch Centrum — Amsterdam, Noord-Holland - NET, Netherlands (enrolling)
- Radboud Universitair Medisch Centrum — Nijmegen, Netherlands (enrolling)
- Wilhelmina Kinderziekenhuis — Utrecht, Netherlands (enrolling)
- Clinica Universidad de Navarra - Madrid — Madrid, Madrid - SPA, Spain (enrolling)
- Clinica Universidad de Navarra - Pamplona — Pamplona, Navarre - SPA, Spain (enrolling)
- Hospital Universitario Virgen del Rocio — Seville, Sevilla - SPA, Spain (enrolling)
- Hospital Universitari i Politecnic La Fe — Valencia, Valencia - SPA, Spain (enrolling)
- University of Alabama at Birmingham School of Medicine — Birmingham, Alabama, United States (enrolling)
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia, United States (enrolling)
- Johns Hopkins All Children's Hospital — St. Petersburg, Florida, United States (enrolling)
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics — Atlanta, Georgia, United States (enrolling)
- Emory University — Atlanta, Georgia, United States (enrolling)
- National Institute of Allergy and Infectious Diseases (NIAID) — Rockville, Maryland, United States (enrolling)
- Columbia University — New York, New York, United States (enrolling)
- Cornell University — New York, New York, United States (enrolling)
- Hackensack University Medical Center — New York, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
- Cleveland Clinic Main Campus — Cleveland, Ohio, United States (enrolling)
- Thomas Jefferson University — Philadelphia, Pennsylvania, United States (enrolling)
- Texas Children's Hospital — Houston, Texas, United States (enrolling)
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Huntsman Cancer Institute — Salt Lake City, Utah, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.